Pharmaceuticals, Biotechnology and Life Sciences
Cellectis has had first patient dosed with off-the-Shelf UCARTCS1 product candidate for relapsed/refractory multiple myeloma.
Verastem Oncology has reported $9 Million in total revenue, including $4.0 Million in net product revenue from COPIKTRA®; Reaffirms FY2019…
Seattle Genetics has record Adcetris net sales in U.S. and Canada of $167.6 Million in the third quarter, an increase…
European Commission has approved a third indication for Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is also approved for moderate-to-severe atopic dermatitis and severe asthma.
Blueprint Medicines Corporation said in an update on its New Drug Application (NDA) for avapritinib for the treatment of adults with PDGFRA , that the FDA has said it plans to administratively split the proposed indications for avapritinib into two separate NDAs, one for PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and one for fourth-line GIST.
FDA has expanded the duration of use of Allergan’s Lilleta to prevent pregnancy for up to six years, after Supplemental…
Medpace Holdings has posted revenue of $216.2 million in the third quarter of 2019, as it increased 20.6% from revenue…
Progenity has presented data on a study showing the potential for improved efficacy in treating inflammatory bowel disease (IBD) when…
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni…
Mirum Pharmaceuticals has appointed Ed Tucker as Chief Medical Officer, the company said Monday.